No information is available on the clinical use of ponatinib during breastfeeding. Because ponatinib is more than 99% bound to plasma proteins, the amount in milk is likely to be low. However, its half-life is about 24 hours and it might accumulate in the infant. National Comprehensive Cancer Network guidelines recommend avoiding breastfeeding during ponatinib therapy and the manufacturer recommends withholding breastfeeding for 6 days following the last dose.[1]
关于泊那替尼在母乳喂养期间的临床应用尚无可用信息。由于泊那替尼与血浆蛋白的结合率超过99%，乳汁中的含量可能较低。然而，其半衰期约为24小时，可能会在婴儿体内蓄积。美国国立综合癌症网络指南建议在泊那替尼治疗期间避免母乳喂养，制造商建议在最后一剂后停止母乳喂养6天。[1]
